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Abstract 11 
Background: Telephone cognitive-behaviour therapy (TCBT) may be a cost-effective 12 
method for improving access to evidence-based treatment for obsessive-compulsive disorder 13 
(OCD) in young people.  14 
Aims: Economic evaluation of TCBT compared to face-to-face CBT for OCD in young 15 
people. 16 
Method: Randomised non-inferiority trial comparing TCBT to face-to-face CBT for 72 17 
young people (aged 11 to 18) with a diagnosis of OCD. Cost-effectiveness at 12-month 18 
follow-up was explored in terms of the primary clinical outcome (CY-BOCS) and quality-19 
adjusted life-years (QALYs).  20 
Results: Total health and social care costs were higher for face-to-face CBT (mean total cost 21 
£2965, SD £1548) than TCBT (mean total cost £2475, SD £1024) but this difference was 22 
non-significant (p=0.118). There were no significant between-group differences in QALYs or 23 
the CY-BOCS and there was strong evidence to support the clinical non-inferiority of TCBT. 24 
Cost-effectiveness analysis suggests a 74% probability that face-to-face CBT is cost-effective 25 
compared to TCBT in terms of QALYs, but the result was less clear in terms of CY-BOCS, 26 
with TCBT being the preferred option at low levels of willingness to pay and the probability 27 
of either intervention being cost-effective at higher levels of willingness to pay being around 28 
50%.  29 
Conclusions: Although cost-effectiveness of TCBT was sensitive to the outcome measure 30 
used, TCBT should be considered a clinically non-inferior alternative when access to 31 
standard clinic-based CBT is limited, or when patient preference is expressed. 32 
Declaration of interest 33 
Prof. Mataix-Cols reports research grants from the Swedish Research Council 34 
(Vetenskapsrådet), the Swedish Research Council for Health, working life and welfare 35 
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(Forte), the US National Institute of Mental Health (NIMH), the UK National Institute of 36 
Health Research (NIHR), as well as royalties from Wolters Kluwer Health and Elsevier, all 37 
unrelated to the submitted work. All other authors report no conflicts of interest. 38 
 39 
40 
4 
 
Introduction     41 
Obsessive-compulsive disorder (OCD) is a serious and disabling disorder which often begins 42 
in childhood.1,2 OCD causes significant disruption to the child’s academic, family and social 43 
life, and impairs the child’s cognitive and psychosocial development.2-4 Because OCD is 44 
often a chronic condition, it imposes substantial long-term economic and social burdens at 45 
both the individual and national levels.5,6 The direct ($2.1 billion) and indirect costs ($6.2 46 
billion) of OCD was estimated to be $8.4 billion a year in 1990 USD prices, accounting for 47 
5.7% of the costs of all mental illnesses.5 In the UK, the total costs of anxiety disorders 48 
(service costs and lost earnings), including OCD, was projected to be £14.2 billion (at 2007 49 
prices) in 2026.6 Despite the well-documented effectiveness of cognitive-behaviour therapy 50 
(CBT) in treating this patient group,7 under-diagnosis and under-treatment are common, 51 
partly due to inequalities in access to treatment.8-11 Following the call from the National 52 
Service Framework for Mental Health to improve accessibility of effective treatments for 53 
common mental health problems,12 alternative treatment modalities using current 54 
technologies such as telephone and computer are increasingly being researched and 55 
developed.10,13 Evidence in adult OCD suggests that telephone CBT (TCBT) shows 56 
promising advantages over face-to-face CBT in terms of reduced service and patient costs, 57 
and improved accessibility and convenience.14-16 This study reports the results of an 58 
economic evaluation of TCBT in a group of young people with OCD carried out alongside a 59 
randomised controlled trial.17  60 
 61 
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Method 62 
Hypothesis 63 
The economic aim of the trial was to compare the cost-effectiveness of TCBT with face-to-64 
face CBT in treating young people with OCD. We hypothesised that TCBT would be cost-65 
effective at a service level compared to face-to-face CBT.   66 
 67 
Trial design  68 
Participants were recruited by referral from primary care general practitioners, and from 69 
mental health professionals within secondary and tertiary care settings within the National 70 
Health Service (NHS) to a specialist OCD clinic between 2008 and 2011. Information about 71 
the study was conveyed by word of mouth, letter to referring agencies, advertisements 72 
published on webpages of national OCD charities within the UK, and by a research support 73 
organisation within the NHS (the Mental Health Research Network).   74 
 75 
Inclusion criteria were: (a) primary OCD according to DSM-IV criteria,18 (b) a Children’s 76 
Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)19 score of 16 or greater, indicating 77 
moderate to severe impairment, (c) aged 11 to 18 years; (d) medication free or on a stable 78 
dose of medication for a period of 12 weeks or greater, (e) no suicidal intent, drug or alcohol 79 
abuse, or psychotic symptoms, (f) no learning disability or pervasive developmental 80 
disability, (g) need and want CBT, and agreeable to randomisation, and (h) agreeable to 81 
parental involvement in treatment.  Exclusion criteria were: (a) current diagnosis of 82 
psychosis, current alcohol or substance abuse/dependence, (b) English too poor to engage in 83 
treatment, (c) severe disabling neurological disorder, (d) diagnosed global learning disability 84 
or pervasive developmental delay, and (e) characteristics interfering with completion of 85 
treatment within trial (e.g. a life-threatening or unstable medical illness).   86 
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 87 
After initial clinical assessments, eligible participants attended a second clinic appointment 88 
approximately 8 weeks later. Participants who remained symptomatic were randomised to 89 
CBT or TCBT in a 1:1 ratio using a computer-generated randomisation sequence prepared 90 
before the study commenced. There were no restrictions or matching. A repeated measures 91 
design was used and assessments were conducted immediately before treatment (i.e., 92 
baseline), immediately after treatment (i.e., post-treatment), and at follow-up points 93 
scheduled at 3-months, 6-months, and 12-months post-treatment. 94 
  95 
Ethics statement 96 
The study protocol was approved by the Joint South London and Maudsley / Institute of 97 
Psychiatry Research Ethics Committee (08/H0807/12).  98 
 99 
Consent statement 100 
Written informed consent was obtained from all parents and participants over 16 years, and 101 
informed assent from participants under 16 years after a detailed description of the study had 102 
been given.  103 
 104 
Clinical trials registration number 105 
The trial was registered on the International Standard Randomized Controlled Trial Number 106 
Register (ISRCTN27070832).  107 
 108 
Interventions 109 
Treatment consisted of 14 sessions of CBT, lasting approximately 60 minutes, delivered by 110 
six experienced clinical psychologists following a detailed treatment manual. Treatment was 111 
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identical within conditions except that participants randomised to TCBT received all 112 
treatment sessions via telephone. Sessions 1-2 consisted of psycho-education, sessions 3-12 113 
consisted of graduated exposure with response prevention (E/RP) and incorporated various 114 
cognitive strategies as appropriate, sessions 13-14 consisted of relapse prevention and 115 
ongoing symptom management (if required). The treatment protocol incorporated 10 minutes 116 
of parental discussion at the end of each treatment session. Homework E/RP tasks were 117 
assigned between sessions and participants were encouraged to complete daily E/RP. The 118 
treatment protocol has been validated in previous trials.20,21 All 14 sessions were required to 119 
be completed within 17 weeks, allowing illness, missed appointments, or holidays to be 120 
accommodated. Treating therapists received supervision by senior clinical psychologists who 121 
were specialists in CBT for OCD and all sessions (wherever possible) were audio recorded. A 122 
random sample of n=225 (25%) recorded sessions were audited and independently rated for 123 
integrity to protocol. The rate of adherence to the manual was 93% and there were no 124 
differences in adherence ratings between conditions.17   125 
 126 
Outcomes 127 
Research assessments were completed in face-to-face interviews at baseline, post-treatment, 128 
3-months, 6-months and 12-months post-treatment. The primary outcome measure for the 129 
economic evaluation was the Children’s Yale-Brown Obsessive-Compulsive Scale (CY-130 
BOCS),19 which was administered by an independent clinician blinded to treatment 131 
condition. CY-BOCS is a detailed semi-structured clinician administered interview, 132 
incorporating a 10-item inventory of paediatric OCD symptoms severity, and is comprised of 133 
an obsession severity score and compulsion severity score. Using a 5-point scale for each 134 
item (score 0 to 4), the total scores range from 0 to 40, where higher scores indicate worse 135 
outcomes. The CY-BOCS has demonstrated robust psychometric properties, with good 136 
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internal consistency, convergent and divergent validity reported19 and has been shown to 137 
respond to change.  138 
 139 
Secondary analysis explored cost-effectiveness in terms of quality-adjusted life years 140 
(QALYs), using the self-report EQ-5D-3L (5 dimensions, 3 levels) measure of health-related 141 
quality of life.22 The EQ-5D is a generic questionnaire that assesses health-related quality of 142 
life on five dimensions including mobility, self-care, usual activities, pain/discomfort, and 143 
anxiety/depression. Each dimension has three levels, leading to a total of 243 possible health 144 
states, each of which is associated with a score used to calculate QALYs. The questionnaire 145 
also contains a visual analogue scale (VAS) which enables participants to rate their current 146 
health state between zero (worst imaginable health state) and 100 (best imaginable health 147 
state).  148 
 149 
Being a generic health state measure, the EQ-5D allows policy makers to make comparisons, 150 
and most importantly, resource allocation decisions, across competing interventions within 151 
the same patient group or more broadly across different disease areas and populations. The 152 
EQ-5D is used extensively in economic evaluations of mental health disorders, despite a lack 153 
of evidence to support the relevance and validity of the measure in all mental health 154 
populations, particularly young populations. Psychometric assessment of the EQ-5D in young 155 
people with persistent major depression provides evidence of weak to moderate validity and 156 
responsiveness.23 However, further research is needed to test the generalisability of these 157 
results to other child and adolescent mental health populations.23 For this reason, the EQ-5D 158 
is used to supplement results from the primary cost-effectiveness analysis in this study. 159 
 160 
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Costs 161 
Economic data were collected in interview at baseline, post-treatment and 3-month, 6-month 162 
and 12-month follow-ups. The economic evaluation took a health and social care perspective 163 
but additionally included carer costs which were expected to be influenced by treatment 164 
delivery method (telephone or face-to-face). Service use information was recorded using the 165 
Child and Adolescent Service Use Schedule (CA-SUS), which included hospital and 166 
community health and social services, and concomitant psychotropic medications. Travel 167 
costs and productivity losses of the primary carer were recorded using the Carer Service Use 168 
Schedule (CARER-SUS). Both schedules have been designed based on previous economic 169 
evaluations in child and adolescent mental health populations.24,25 All unit costs are reported 170 
in Pound Sterling and were for the financial year 2010-2011, which was the most recent year 171 
over which the trial data were collected. No discounting was necessary due to the short 172 
duration of the trial. 173 
  174 
A nationally applicable unit cost for CBT for young people of £115 per hour of face-to-face 175 
contact was applied to all CBT sessions young people attended in the trial.26 Sessions that 176 
young people did not attend (DNAs) were assumed to have a zero cost on the basis that the 177 
clinician would be able to make use of the time available to do something else. This unit cost 178 
was based on estimates from a randomised controlled trial of interventions for adolescents 179 
with major depression25 and includes the cost of supervision and relevant overheads 180 
(management, administrative, capital, estates etc.). Expert opinion was sought which 181 
confirmed that this unit cost was reasonable, given similarities in the grade and seniority of 182 
the therapists involved and the length of the sessions. In addition, data collected by therapists 183 
at each session, which included session length, confirmed that the average length of time 184 
spent delivering TCBT sessions was equal to that of face-to-face sessions (mean 62 minutes 185 
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in both groups) hence the same cost was applied to both treatment conditions. Costs of 186 
psychotropic medication were taken from the British National Formulary,27 and costs of 187 
hospital contacts, including in-patient and out-patient appointments, and accident and 188 
emergency attendance, were obtained from the National Schedule of Reference Costs.28 189 
Contacts with community health and social services were taken from national publications.26 190 
Unit costs were multiplied by the corresponding service use data to generate total service 191 
costs per patient. 192 
  193 
Productivity losses of the primary carers were valued using the human capital approach.29 194 
This involves multiplying the individual’s salary by hours of absence from work due to their 195 
child’s illness. Travel costs of public transport, such as train and bus, were self-reported in 196 
the CARER-SUS. To estimate travel cost by private car, mileage between the clinic and 197 
home address was multiplied by the national average standing (basic costs of keeping the car 198 
for use on the road, including annual car tax, insurance, cost of capital used for the car and 199 
depreciation) and running (costs that depend directly on using the car, including fuel costs, 200 
parking and tolls, tyres, servicing and repair costs) cost per mile.30  201 
 202 
Statistical method 203 
The trial was designed to test non-inferiority in effects of the two competing interventions, so 204 
one may consider it legitimate to conduct a cost-minimisation analysis (CMA), which is an 205 
analysis method involving comparison of costs alone, given equal outcomes. However, CMA 206 
has been criticised for leading to biased results, causing overestimation or underestimation of 207 
the probability that treatment is cost-effective.31 For this reason, cost-effectiveness analysis 208 
(CEA) is recommended, regardless of non-inferiority, for exploration of uncertainty 209 
surrounding the cost and effectiveness data and to help interpret the economic results.31,32 210 
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  211 
Analyses were carried out on an intention-to-treat basis, with the primary objective of 212 
comparing the costs and cost-effectiveness of TCBT and face-to-face CBT at the final 12-213 
month follow-up point. In order to best utilise all available data, multiple regression was used 214 
to impute missing total cost, QALY and CY-BOCS data in the main cost-effectiveness 215 
analyses using the impute command in STATA. Factors included in the multiple regression 216 
were treatment arm and the following baseline characteristics: gender, age, CY-BOCS scores 217 
and EQ-5D scores. All analyses were adjusted for baseline characteristics including gender, 218 
age, CY-BOCS scores and EQ-5D scores using multiple regression techniques. Results from 219 
the smaller sample with full economic data were reported in sensitivity analyses to explore 220 
the robustness and validity of the imputed data.   221 
 222 
Results from cost-effectiveness analyses were expressed in terms of incremental cost-223 
effectiveness ratios (ICERs), defined as the difference in mean costs divided by the difference 224 
in mean effects, calculated using the net benefit approach.33 Non-parametric bootstrapping 225 
(random and repeat re-sampling from the costs and outcome data) was used to generate a 226 
large number of sets of expected incremental costs and effects for both treatment groups 227 
(1000 replications).29 The proportion of these that were greater than zero gives the probability 228 
that TCBT is the optimal choice, i.e. cost-effective compared to face-to-face CBT, subject to 229 
a range of thresholds which represent decision makers’ willingness-to-pay for a unit 230 
improvement in outcome.  231 
 232 
These probabilities were used to generate cost-effectiveness acceptability curves (CEAC), 233 
which are the recommended alternative to confidence intervals around ICERs to overcome 234 
problems associated with ratio estimators in standard statistical methods.34,35 CEACs account 235 
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for the uncertainty surrounding the estimates of expected costs and outcomes, and act as a 236 
useful tool to inform decision makers on the probability that an intervention will be cost-237 
effective at different thresholds.35 Cost-effectiveness planes were used to illustrate the 238 
distribution of bootstrapped mean differences in costs and outcomes.  239 
 240 
Sensitivity analyses were carried out to investigate the robustness of the economic evaluation, 241 
and to account for uncertainty that exists around some of the input parameters and 242 
assumptions. Firstly, as noted above, a complete case sensitivity analysis was undertaken to 243 
explore the validity of the imputation method used for dealing with missing data. Secondly, 244 
we considered the ongoing debate about the inclusion of various non-healthcare related 245 
costs36 and repeated the economic analyses by employing the NHS and personal social 246 
services perspective preferred by NICE in guideline development, which involved the 247 
removal of all costs borne by the carers. Finally, we considered the hypothesis that face-to-248 
face CBT overhead costs may be higher than TCBT overhead costs as a result of the need for 249 
potentially more expensive clinical space, compared to office space, administrative costs 250 
related to the booking of clinical space, and time spent preparing the clinic space. Whilst the 251 
main analysis was conservative, assuming equal overheads for TCBT and face-to-face CBT, 252 
the sensitivity analysis reduced the cost of TCBT by 10%. 253 
 254 
Results 255 
Participants 256 
72 participants were recruited into the trial, 36 randomised to TCBT and 36 to face-to-face 257 
CBT. Baseline demographic and clinical characteristics of the two treatment groups are 258 
shown in the online supplement. The current paper focuses on the economic results; further 259 
detail on participant characteristics and clinical results are reported elsewhere.17 260 
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 261 
At final 12-month follow-up, full clinical data was available for 27 (75%) participants in the 262 
CBT group and 25 (69%) participants in the TCBT group and full economic data was 263 
available for 21 (58%) in the CBT group and 22 (61%) in the TCBT group. Comparison of 264 
baseline characteristics between those with available and those with missing data revealed a 265 
significant difference in baseline CY-BOCS scores (p=0.033), with those missing having 266 
poorer baseline scores, but no differences in any other variables. 267 
 268 
Outcomes 269 
For the primary clinical outcome, CY-BOCS, at all assessment points through to six-month 270 
follow-up, the difference between conditions was non-significant and the 95% confidence 271 
interval lies below the 5-point difference margin, indicating that TCBT was not inferior to 272 
face to face CBT. For the 12-month follow-up point, the difference remained non-significant 273 
but non-inferiority of TCBT could not conclusively be demonstrated as the 95% confidence 274 
interval included the margin of difference.17 All secondary measures included in the clinical 275 
trial confirmed non-inferiority at all assessment points.17 276 
 277 
Table 1 reports the results for the EQ-5D. Both groups show improvements in health-related 278 
quality of life over time but there were no significant differences between the groups.  279 
 280 
Table 1 here 281 
 282 
Resource Use 283 
Mean number of service contacts for participants with full economic data over the treatment 284 
and 12-month follow-up period are shown in the online supplement. There were few 285 
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differences in service utilisation between the two groups, although participants in the face-to-286 
face CBT group had slightly more outpatient appointments and more contacts with 287 
community health and social services than those in the TCBT group, particularly GP and 288 
clinical psychologist contacts. Despite the different modes of delivery, intervention 289 
attendance was similar in each group (12.3 sessions in the face-to-face CBT group versus 290 
12.8 sessions in the TCBT group out of a possible 14 sessions). 291 
 292 
Total costs 293 
Total costs per participant over the treatment and 12-month follow-up period are reported in 294 
Table 1. Intervention costs were similar in the two groups, as a result of the similar number of 295 
sessions attended (mean cost in CBT group £1476, SD 289; mean cost in TCBT group £1415, 296 
SD 307). On average, total cost per participant in the face-to-face CBT group was £2965 (SD 297 
1548), which was £490 more costly than the TCBT group (£2475, SD 1024). This difference 298 
was not statistically significant (p=0.118).  For both groups, the CBT interventions accounted 299 
for the greatest proportion of the total costs (53%), followed by carer costs (20%) and 300 
hospital services (16%).  301 
 302 
Carer costs were relatively low and differed little between groups. Only a small proportion of 303 
parents reported taking any time off work (n=13 at the post-treatment follow-up point) and 304 
travel costs reported in the face-to-face CBT group were small. 305 
 306 
Cost-effectiveness analysis 307 
Figure 1 shows a scatterplot of the bootstrapped replications for incremental cost and 308 
incremental CY-BOCS score for TCBT on the cost-effectiveness plane. Because lower CY-309 
BOCS scores are associated with improved outcomes, the standard cost-effectiveness plane is 310 
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reversed (outcomes deteriorate when moving from left to right on the x-axis). Compared to 311 
TCBT, face-to-face CBT has higher bootstrapped mean cost per participant (£697) and 312 
slightly better bootstrapped mean effects on the CY-BOCS (-0.07367), giving rise to an ICER 313 
of £9461 per unit reduction (improvement) in CY-BOCS. In other words, a one-point 314 
improvement in CY-BOCS can be realized if decision makers are willing to pay an additional 315 
£9461 for face-to-face CBT.  316 
 317 
It should be noted that, whilst the cost-effectiveness results presented are based on a unit 318 
improvement in CY-BOCS, a clinically meaningful reduction in symptoms has been 319 
suggested to be at least a 35% reduction in CY-BOCS score.37 Taking the minimum for 320 
inclusion in this study of a CY-BOCS score of 16, a 35% reduction would be 6 points. Thus, 321 
whilst the incremental cost per unit improvement in CY-BOCS is £9,461, willingness to pay 322 
for a clinically meaningful improvement would need to be a minimum of £56,766 for face-to-323 
face CBT to be considered cost-effective compared to TCBT using the CY-BOCS. This 324 
minimum would increase with increasing severity of impairment at baseline. For example, 325 
taking the average baseline score for trial participants of approximately 25, a 35% reduction 326 
would be equivalent to approximately 9 points on the CY-BOCS and thus willingness to pay 327 
for a clinically meaningful improvement would need to be at least £85,149 per participant for 328 
face-to-face CBT to be considered cost-effective compared to TCBT. 329 
 330 
The results for QALYs are shown in Figure 2, where, in this case, lower scores are associated 331 
with poorer outcomes so the standard cost-effectiveness plane applies (outcomes improve 332 
when moving from left to right on the x-axis). Face-to-face CBT was again associated with 333 
higher bootstrapped mean cost per participant (£697) and improved bootstrapped mean 334 
effects in QALY (0.0794) compared to TCBT, giving rise to an ICER of £8778 per unit 335 
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increase in QALY. Thus for both measures of outcome, TCBT is associated with lower costs 336 
but also slightly poorer outcomes. 337 
 338 
Figures 1 and 2 here 339 
 340 
The cost-effectiveness acceptability curves (CEAC) shown in Figure 3 illustrate that at the 341 
standard NICE willingness-to-pay threshold of £20,000 per QALY (NICE, 2008), the 342 
probability of TCBT being the dominant option is 26% and thus the probability of face-to-343 
face CBT being cost-effective compared to TCBT is 74%. There is no clear consensus 344 
threshold for a unit improvement in CY-BOCS. Figure 3 suggests that at low levels of 345 
willingness to pay (£4000 and below), there is a higher probability of TCBT being the cost-346 
effective option. However, as willingness to pay rises above this amount, the probability of 347 
either intervention being cost-effective is around 50%.   348 
 349 
Figure 3 here 350 
 351 
Sensitivity analyses 352 
Sensitivity analyses, reported in the online supplement, did not alter the overall findings of 353 
the cost-effectiveness analyses. The complete case and the narrower NHS/social services 354 
perspective reduced the mean cost per participant in each group, but the difference between 355 
groups remained very similar (£490 primary analysis; £542 complete case analysis; £421 356 
narrow perspective) and these differences remained non-significant. Differences in costs 357 
became statistically significant between the two groups when the cost of TCBT was reduced 358 
by 10% to £104 per session (mean difference £631, p=0.044). However, this did not alter the 359 
cost-effectiveness results.  360 
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 361 
Discussion 362 
The results of this economic evaluation, and the associated clinical trial,17 suggest there is 363 
strong evidence to support the clinical non-inferiority of TCBT compared to face-to-face 364 
CBT for young people with OCD, and no evidence to suggest any statistically significant 365 
differences in total cost per participant between the two groups, albeit with lower observed 366 
costs in the TCBT group.   367 
 368 
In terms of cost-effectiveness, whilst our secondary cost-effectiveness analysis based on 369 
QALYs favoured face-to-face CBT, our primary cost-effectiveness analysis based on the CY-370 
BOCS was less clear. This analysis suggests that TCBT may be the preferred option at low 371 
levels of willingness to pay for additional improvements in CY-BOCS scores, whilst at 372 
higher levels of willingness to pay, the probability of either intervention being cost-effective 373 
is around 50%.  374 
 375 
Taking into consideration evidence to suggest that TCBT is clinically non-inferior to CBT, 376 
evidence from our primary cost-effectiveness analysis to suggest TCBT has a 50% or higher 377 
probability of being cost-effective compared to face-to-face CBT, and potential cost-savings 378 
for TCBT, which were statistically significant in sensitivity analysis hypothesising a 10% 379 
reduction in the cost of TCBT given the potential for lower overhead costs, TCBT presents as 380 
an effective alternative for young OCD sufferers who are unable or unwilling to access face-381 
to-face CBT.  382 
There are a number of limitations of the work presented. First, there is currently no evidence 383 
of the validity or responsiveness of the EQ-5D in young people with OCD, and some 384 
evidence to suggest that the youth version of the EQ-5D (EQ-5D-Y) is not correlated with 385 
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clinical outcomes in such populations,38 so the sensitivity of the EQ-5D to clinically 386 
important changes is in doubt. Lack of sensitivity of broadly focused outcome measures 387 
compared to disease-specific measures has been demonstrated in a previous paediatric OCD 388 
population,39 so this is a real possibility in the current sample. However, both measures of 389 
effect showed consistent improvements over the post-treatment and follow-up periods and 390 
there were no significant between-group differences. This suggests that the EQ-5D may be a 391 
relatively robust and sensitive measure of effect in this patient group, though more research is 392 
required to substantiate this. 393 
 394 
Sample sizes, estimated for the purpose of the primary clinical question,17 were small, and 395 
thus the economic evaluation may have been underpowered. We attempted to minimise the 396 
further impact of data loss through imputation of missing data and, although the imputation 397 
method was robust in sensitivity analysis, results of the study still require careful 398 
interpretation due to the small sample sizes and large amount of missing economic data at the 399 
12-month follow-up. Significant differences in the baseline CY-BOCS scores (p=0.033) were 400 
found between those with missing data and those with full economic data, with those missing 401 
having marginally higher symptom scores at baseline, although this was less than 2 points on 402 
the CY-BOCS scale which is unlikely to be clinically meaningful. No significant differences 403 
were detected in any other baseline characteristics.  404 
 405 
Data collected at each therapy session confirmed that there were no differences in terms of 406 
length of sessions, grade of therapists and thus costs, between TCBT and face-to-face CBT, 407 
and that CBT sessions in young people with OCD are comparable to those with major 408 
depression, which is what the unit cost applied was based on. However, a more detailed 409 
micro-costing (bottom-up) in future research may still be valuable as it would provide more 410 
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accurate estimates of treatment costs. In an attempt to compensate for the lack of a micro-411 
costing approach, and the hypothesis that overhead costs associated with TCBT may be lower 412 
than those for face-to-face CBT, the cost of TCBT was reduced by 10% in sensitivity 413 
analysis, and the cost results, although not the cost-effectiveness results, were found to be 414 
sensitive to this parameter.  415 
 416 
In terms of generalisability, all treatments within the trial were delivered by NHS therapists 417 
to NHS patients aged 11 to 18 with a clinical diagnosis of OCD. However, this was a single 418 
site study based in a specialist clinic in London, so generalisability across the UK or other 419 
countries is not proven. 420 
 421 
Finally, the trial enabled comparisons to be made in terms of improving access to treatment 422 
by attempting to remove geographical, social or financial barriers, between the two delivery 423 
modes for CBT in young people with OCD. It was not, however, designed to quantify the 424 
effect of TCBT on commonly long NHS waiting lists that result from therapist shortage.10 425 
Since with greater access comes greater demands, improvement in access via waiting list 426 
reduction could only be achieved in this patient group if TCBT is proven to save therapists’ 427 
time, and if the treatment could be delivered by more therapists through increased training 428 
and effective dissemination of clinical and training materials.9 Thus, the implications for the 429 
NHS in terms of availability of resources to provide such service and the impact of such 430 
provision on the NHS waiting list remain unclear. The full economic impact of TCBT in 431 
reducing waiting time or delayed access is unknown and further research is needed. 432 
Similarly, the analysis does not take into consideration resource implications in terms of 433 
therapist location, with face-to-face CBT requiring therapy rooms which are often in great 434 
demand, compared to TCBT which can take place at a desk. 435 
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 436 
Policy implications 437 
There is no evidence to suggest that TCBT is cost-effective compared to face-to-face, clinic-438 
based CBT in this study, particularly in terms of QALYs, and therefore TCBT may not be the 439 
preferred strategy of policy makers by default. However, taking into consideration the non-440 
inferiority of effects, the potential for cost savings and the potential to overcome barriers to 441 
treatment, it should be recognised that TCBT has a place in supporting the government’s 442 
initiative to increase accessibility of effective treatments for OCD12 and should be offered 443 
where access to specialist clinic-based CBT is limited or where patient or family preference 444 
for telephone therapy is high.  445 
 446 
It is also important to consider the generalisability of the results and the context within which 447 
the study was undertaken. The study is not able to come to conclusions about the cost-448 
effectiveness of TCBT for young people who were excluded from the study including those 449 
with mild impairment, with current alcohol or substance abuse or dependence, with psychosis 450 
or psychotic symptoms, or with chaotic medication use. In addition, the study is not able to 451 
come to any conclusion about the cost-effectiveness of TCBT in more rural settings, where 452 
specialist clinic-based services are likely to be particularly inaccessible.  453 
 454 
Further research priorities in this field include (1) comparison of the cost-effectiveness of 455 
TCBT with other less resource-intensive modes of delivering evidence-based treatments, 456 
such as computerised or internet-based CBT for OCD13,37 or therapist supported self-help 457 
programmes,10 (2) investigation of the cost-effectiveness and feasibility of TCBT delivered 458 
by other health professionals within the community setting, such as CBT-trained nurses 459 
(mental health nurse or practice-based nurse), or generic CAMHS therapists, and (3) 460 
21 
 
replication of the study with a larger sample of participants recruited from multiple sites, 461 
including both rural and urban sites.  462 
 463 
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Table 1: Outcomes and costs by treatment groups 619 
 CBT 
(n=36) 
TCBT 
(n=36) 
  
 Mean (s.d.) Mean (s.d.) Mean difference (95% CI) p-value 
EQ-5D VAS     
Baseline 7.52 (1.45) 7.85 (1.63) -0.33 (-1.06 to 0.39) 0.366 
Post-treatment 8.75 (1.30) 8.48 (1.51) 0.27 (-0.39 to 0.94) 0.412 
Final follow-up 8.91 (0.71) 9.10 (0.75) -0.19 (-0.53 to 0.15) 0.277 
EQ-5D Utilities     
Baseline 0.76 (0.15) 0.80 (0.27) -0.04 (-0.15 to 0.06) 0.396 
Post-treatment 0.89 (0.14) 0.89 (0.22) -0.00 (-0.08 to 0.09) 0.952 
Final follow-up 0.93 (0.08) 0.91 (0.08) 0.01 (-0.02 to 0.05) 0.379 
QALYs     
Final follow-up 1.19 (0.21) 1.14 (0.29) 0.05 (-0.07 to 0.17) 0.379 
Costs between baseline and 12-month post-treatment follow-up (£) 
Intervention 1476 (289) 1415 (307) 61 (-79 to 201) 0.391 
Hospital services 550 (1040) 313 (532) 237 (-152 to 625) 0.229 
Community services 330 (406) 233 (233) 98 (-61 to 250) 0.230 
Medication 40 (110) 14 (5) 19 (-12 to 63) 0.176 
Carer cost 569 (658) 500 (692) 69 (-249 to 386) 0.666 
Total cost 2965 (1548) 2475 (1024) 490 (-127 to 1107) 0.118 
VAS=visual analogue scale; QALY=quality adjusted life years 620 
 621 
622 
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Figure 1: Bootstrapped mean differences in costs and effects in term of CY-BOCS for TCBT 623 
compared to face-to-face CBT 624 
 625 
 626 
Note: Standard cost-effectiveness plane is reversed as higher CY-BOCS scores reflect poorer outcomes 627 
628 
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Figure 2: Bootstrapped mean differences in costs and effects in term of QALYs for TCBT 629 
compared to face-to-face CBT 630 
 631 
 632 
633 
32 
 
Figure 3: Cost-effectiveness acceptability curves showing the probability that TCBT is cost-634 
effective compared to face-to-face CBT 635 
 636 
637 
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Section/item 
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effectiveness 
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based outcomes 
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Estimating resources and 
costs 
13a Single study-based economic evaluation:Describe 
approaches used to estimate resource use 
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Describe primary or secondary research methods 
for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to 
approximate to opportunity costs. 
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13b Model-based economic evaluation: Describe 
approaches and data sources used to estimate 
resource use associated with model health states. 
Describe primary or secondary research methods 
for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to 
approximate to opportunity costs. 
N/A 
Currency, price date, and 
conversion 
14 Report the dates of the estimated resource 
quantities and unit costs. Describe methods for 
adjusting estimated unit costs to the year of 
reported costs if necessary. Describe methods for 
converting costs into a common currency base 
and the exchange rate. 
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Choice of model 15 Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure 
to show model structure is strongly 
N/A 
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recommended. 
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Analytical methods 17 Describe all analytical methods supporting the 
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with skewed, missing, or censored data; 
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and uncertainty. 
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Results 
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to represent uncertainty where appropriate. 
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Online supplement, 
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Incremental costs and 
outcomes 
19 For each intervention, report mean values for the 
main categories of estimated costs and outcomes 
of interest, as well as mean differences between 
the comparator groups. If applicable, report 
incremental cost-effectiveness ratios. 
Page 29, table 1; 
Page 13, line 272 to 282; 
Page 14, line 296 to 308 
 
Characterising 
uncertainty 
20a Single study-based economic evaluation:Describe 
the effects of sampling uncertainty for the 
estimated incremental cost and incremental 
effectiveness parameters, together with the 
impact of methodological assumptions (such as 
discount rate, study perspective). 
Page 16, line 355 to 363; 
Online supplement, 
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page 30, figure 1; 
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page 32, figure 3   
20b Model-based economic evaluation: Describe the 
effects on the results of uncertainty for all input 
parameters, and uncertainty related to the 
structure of the model and assumptions. 
N/A 
Characterising 21 If applicable, report differences in costs, 
outcomes, or cost-effectiveness that can be 
N/A 
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heterogeneity explained by variations between subgroups of 
patients with different baseline characteristics or 
other observed variability in effects that are not 
reducible by more information. 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how 
they support the conclusions reached. Discuss 
limitations and the generalisability of the findings 
and how the findings fit with current knowledge. 
page 17, line 365 to 
page 19, line 438; 
page 20 line 440 to page 
21 line 465; 
Other 
Source of funding 23 Describe how the study was funded and the role 
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Page 22, lines 472 to 476  
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